These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34348844)

  • 21. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis.
    Patterson BJ; Chen CC; McGuiness CB; Ma S; Glasser LI; Sun K; Buck PO
    J Am Pharm Assoc (2003); 2022; 62(2):526-536.e10. PubMed ID: 34893442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
    Hesse EM; Shimabukuro TT; Su JR; Hibbs BF; Dooling KL; Goud R; Lewis P; Ng CS; Cano MV
    MMWR Morb Mortal Wkly Rep; 2019 Feb; 68(4):91-94. PubMed ID: 30703077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which patients should receive the herpes zoster vaccine?
    Short MD; Fergus C
    JAAPA; 2019 Sep; 32(9):18-20. PubMed ID: 31460969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine.
    Hurley LP; O'Leary ST; Dooling K; Anderson TC; Crane LA; Cataldi JR; Brtnikova M; Beaty BL; Gorman C; Guo A; Lindley MC; Kempe A
    J Gen Intern Med; 2023 Mar; 38(4):986-993. PubMed ID: 35794307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
    Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
    J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States.
    Curran D; La EM; Salem A; Singer D; Lecrenier N; Poston S
    Hum Vaccin Immunother; 2022 Dec; 18(1):2027196. PubMed ID: 35049412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data.
    Nelson JC; Ulloa-Pérez E; Yu O; Cook AJ; Jackson ML; Belongia EA; Daley MF; Harpaz R; Kharbanda EO; Klein NP; Naleway AL; Tseng HF; Weintraub ES; Duffy J; Yih WK; Jackson LA
    Am J Epidemiol; 2023 Feb; 192(2):205-216. PubMed ID: 36193854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
    Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
    Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007-2014.
    Tsai Y; Lindley MC; Zhou F; Stokley S
    Prev Med Rep; 2019 Sep; 15():100917. PubMed ID: 31223560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment.
    Patterson BJ; Myers K; Stewart A; Mange B; Hillson EM; Poulos C
    Expert Rev Vaccines; 2021 Jun; 20(6):729-741. PubMed ID: 33902368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster.
    Sly JR; Harris AL
    Nurs Womens Health; 2018 Oct; 22(5):417-422. PubMed ID: 30145235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older.
    Ackerson B; Qian L; Sy LS; Bruxvoort K; Wu J; Luo Y; Diaz-Decaro J; Talarico C; Tseng HF
    Vaccine; 2021 Feb; 39(6):926-932. PubMed ID: 33441234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing and Improving Zoster Vaccine Uptake in a Homeless Population.
    Kaplan-Weisman L; Waltermaurer E; Crump C
    J Community Health; 2018 Dec; 43(6):1019-1027. PubMed ID: 29730833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
    Sun Y; Jackson K; Dalmon CA; Shapiro BL; Nie S; Wong C; Arnold BF; Porco TC; Acharya NR
    Vaccine; 2021 Jun; 39(29):3974-3982. PubMed ID: 34116874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    Satyam VR; Li PH; Reich J; Qazi T; Noronha A; Wasan SK; Farraye FA
    Dig Dis Sci; 2020 Oct; 65(10):2986-2991. PubMed ID: 31897892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.